title: Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients.
authors.affiliation: Department of Internal Medicine, Section of Immunoallergology and Respiratory Diseases, University of Florence, Policlinico di Careggi Viale Morgagni 85, 50134 Florence, Italy. a.matucci@dmi.unifi.it
authors.forename: A
authors.initials: A
authors.lastname: Matucci
authors.forename: P
authors.initials: P
authors.lastname: Parronchi
authors.forename: A
authors.initials: A
authors.lastname: Vultaggio
authors.forename: O
authors.initials: O
authors.lastname: Rossi
authors.forename: F
authors.initials: F
authors.lastname: Brugnolo
authors.forename: E
authors.initials: E
authors.lastname: Maggi
authors.forename: S
authors.initials: S
authors.lastname: Romagnani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology*; D003429:Cross Reactions; D016861:Cyclooxygenase Inhibitors / Q000276:immunology*; D004342:Drug Hypersensitivity / Q000276:immunology*; D005260:Female; D006801:Humans; D007783:Lactones / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013450:Sulfones / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib